Sarepta Therapeutics (NASDAQ:SRPT) and the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) have entered
into a Cooperative Research and Development Agreement (CRADA) to
jointly identify antisense oligonucleotides using Sarepta’s
phosphorodiamidate morpholino oligomer (PMO) platform with activity
against SARS-CoV-2 for the potential treatment of COVID-19.
Pursuant to the CRADA, Sarepta will design,
synthesize, manufacture and provide multiple peptide-conjugated PMO
constructs based on genetic sequencing of SARS-CoV-2 for COVID-19.
USAMRIID will evaluate the constructs for their
potential to inhibit viral infection. Based on the results, funding
proposals will be considered to advance the development of treatments
for COVID-19.
https://seekingalpha.com/news/3565259-sarepta-up-5-premarket-on-covidminus-19-plan
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.